US Dermatological Therapeutics Market is at around $16.88 Bn in 2023 and is projected to reach $26.40 Bn in 2030, exhibiting a CAGR of 6.6% during the forecast period. The development of innovative therapies, the growing trend of cosmetic dermatology, and the increasing prevalence of skin conditions are driving the growth of the market. The market is dominated by key players like Almirall SA, Pfizer Inc., AbbVie Inc., Amgen, Gladerma SA, Johnson & Johnson, Novartis AG, Eli Lily and Company, Sun Pharmaceuticals Ltd., and GlaxoSmithKline PLC.
US Dermatological Therapeutics Market is at around $16.88 Bn in 2023 and is projected to reach $26.40 Bn in 2030, exhibiting a CAGR of 6.6% during the forecast period.
Dermatological Therapeutics is dedicated to the identification and management of skin conditions. It includes a broad spectrum of therapeutic and aesthetic procedures intended to treat several types of dermatological disorders, including tumors, inflammatory diseases, and infections. Surgical procedures, laser therapy, topical or systemic drugs, and other cutting-edge methods can all be part of dermatological therapeutics. Restoring or maintaining the skin's health and look while taking care of aesthetic and medical issues is the aim. Dermatologists are experts at using evidence-based treatments to give their patients the best possible results.
The US market for dermatological therapies is well-established and experiencing growth due to increased consumer demand for advanced skin-related therapies. One in four Americans, or 84.5 Mn people, suffered from a skin condition. Its dynamic and developing nature is attributed to several factors, including technological improvements, an aging population, and their emphasis on customized dermatological treatments. Leading companies keep coming up with innovative concepts and providing a variety of product lines to treat a broad spectrum of skin disorders.
Revenues from the dermatological treatments market have increased dramatically, reaching $40.94 Bn worldwide in 2023. Revolutionizing the industry, this growth is driven by cost-effective production techniques and transformational technologies. The dynamic confluence of innovation, accessibility, and financial support is reflected in the changing landscape, which has shaped the dermatological treatment market into a thriving and resilient domain.
Currently undergoing Phase 3 trials for moderate-to-severe plaque psoriasis, Amgen's AMG 4375, an IL-17A inhibitor, has demonstrated encouraging efficacy in removing skin lesions. Phase 2 trials for hidradenitis suppurativa, a chronic inflammatory skin disorder, are being conducted on AMG 9557, another IL-17A inhibitor.
Market Growth Drivers:
Development of Innovative Therapies: New and more effective treatments for a range of skin problems are being developed as a result of ongoing breakthroughs in pharmaceutical and medical technologies. This promotes income generation and market expansion.
Growing Trend of Cosmetic Dermatology: With the expanding trend, procedures like Botox, dermal fillers, and laser treatments have increased demand for cosmetic dermatological products and services, thus leading to the growth of the market.
High Prevalence Skin Conditions: Millions of people in the US suffer from a high prevalence of chronic skin disorders like psoriasis, eczema, and acne. The market is growing because of the continuous need for therapy.
Market Restraints:
Strict FDA Approval Procedure: The FDA's stringent safety and efficacy requirements make it a costly and time-consuming process to bring new treatments to market. This may impede smaller businesses' access to the market and deter investment in novel medications.
Post-marketing Surveillance: Continued safety inspections and possible risk-benefit analyses may result in the withdrawal or restriction of a product, which would affect sales and create uncertainty in the market.
Availability of Generic Drugs: When branded medications lose their patent exclusivity, less expensive generic substitutes become available, which drives down prices and lowers profits for the original producers.
The US regulatory body in charge of policing dermatological drugs is the Food and Drug Administration (FDA). The FDA ensures that new drugs are safe and effective by evaluating and approving them. For the majority of novel therapeutic drugs and biologics, the development process consists of three primary stages: pre-clinical, clinical, and FDA review. The process of obtaining a license for a drug is fraught with difficulties, including stringent restrictions, lengthy and costly development timeframes, and difficulties in clinical trials.
Key Players:
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Type
By Disease
By Drug Class
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.